摘要
目的评价我国急性软组织损伤患者的健康相关生命质量并分析其影响因素。方法使用五水平五维健康量表(EQ-5D-5L)对我国12家医院的480例急性软组织损伤患者进行健康生命质量调查,并基于我国EQ-5D-5L效用积分体系转化为健康效用值。采用线性回归模型进行多因素分析,对急性软组织损伤患者健康效用值的影响因素进行探索。结果共纳入480例患者,平均年龄为38.86岁,无疼痛、轻微疼痛、中度疼痛、剧烈疼痛状态的急性软组织损伤患者健康效用值分别为0.99、0.90、0.69、0.62。急性软组织损伤对患者的疼痛/不舒服维度影响最大,对患者的活动性维度影响有限,对患者的心理影响较小。对急性软组织损伤患者健康效用值影响显著的因素有性别、体重指数、既往病史、静息VAS评分及脉象。结论相较于心理方面,急性软组织损伤对患者生理方面的影响程度更大。在日常运动中,BMI较低,或有基础疾病的人群应正确选择运动方式,避免急性软组织损伤的发生,造成生命质量下降。
Objective To evaluate the health-related quality of life of patients with acute soft tissue injury in China and analyze its influencing factors.Methods A survey was conducted on 480 patients with acute soft tissue injury in 12 hospitals in China.The EQ-5D-5L scale was used to measure the quality of life in health,and the health utility value was converted based on the EQ-5D-5L utility integral system in China.A linear regression model was used for multivariate analysis to explore the influencing factors on the health utility value of patients with acute soft tissue injury.Results A total of 480 patients were included in the study,with an average age of 38.86 years.The utility values of patients with acute soft tissue injury in painless,mild,moderate,and intense pain states were 0.99,0.90,0.69,and 0.62,respectively.Acute soft tissue injury has the greatest impact on the patient's pain/discomfort dimension,limited impact on the patient's activity dimension,and minimal psychological impact on the patient.The factors that significantly affect the utility value of acute soft tissue patients include gender,body mass index(BMI),medical history,resting pain score,and pulse.Conclusion Compared to psychological factors,acute soft tissue injury has a greater impact on the physiological aspects of patients.In daily exercise,individuals with lower BMI or underlying diseases should choose the correct exercise method to avoid the occurrence of acute soft tissue injury,which can lead to a decrease in quality of life.
作者
曹林林
范长生
郑美萍
刘新颖
刘抚瑶
陈斌斌
CAO Lin-Lin;FAN Chang-Sheng;ZHENG Mei-Ping;LIU Xin-Ying;LIU Fu-Yao;CHEN Bin-Bin(Pharmacy College of Zhejiang Pharmaceutical Vocational University,Ningbo 315500,China;Beijing Institute of Medical and Health Economics,Beijing 100069,China;School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处
《中国药物经济学》
2024年第4期5-8,16,共5页
China Journal of Pharmaceutical Economics